TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07225621: Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Sponsor: Alpheus Medical, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 103 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,032,800

Rescue Site Savings

+$1,339,800

Unlock Full NCT07225621 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07225621 Rescue Dossier →